Rituxan Hycela FDA Approval History
FDA Approved: Yes (First approved June 22, 2017)
Brand name: Rituxan Hycela
Generic name: rituximab and hyaluronidase human
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Follicular Lymphoma; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia
Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).
Development timeline for Rituxan Hycela
| Date | Article |
|---|---|
| Jun 22, 2017 | Approval FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
